Literature DB >> 2685299

A double blind crossover placebo controlled trial of ximoprofen in as.

M Dougados, R Caporal, P Doury, A Thiesce, S Pattin, B Laffez, B Amor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2685299

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

Review 1.  Conventional treatments for ankylosing spondylitis.

Authors:  M Dougados; B Dijkmans; M Khan; W Maksymowych; Sj van der Linden; J Brandt
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 2.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].

Authors:  U Kiltz; J Sieper; H Kellner; D Krause; M Rudwaleit; J-F Chenot; A Stallmach; S Jaresch; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 4.  Treatment trials in ankylosing spondylitis: current and future considerations.

Authors:  D van der Heijde; J Braun; D McGonagle; J Siegel
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

5.  [Treatment of chronic back pain: current standards].

Authors:  E Märker-Hermann; U Kiltz; J Braun
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

Review 6.  Pharmacological treatment of ankylosing spondylitis: a systematic review.

Authors:  Pauline Boulos; Maxime Dougados; Stuart M Macleod; Elke Hunsche
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment.

Authors:  Saeed A Shaikh
Journal:  J Can Chiropr Assoc       Date:  2007-12

8.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 9.  Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Authors:  Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde
Journal:  Cochrane Database Syst Rev       Date:  2015-07-17

10.  Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.

Authors:  John Oldroyd; Lionel Schachna; Rachelle Buchbinder; Margaret Staples; Bridie Murphy; Molly Bond; Andrew Briggs; Marissa Lassere; Lyn March
Journal:  Int J Rheumatol       Date:  2009-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.